Opinion statement
The management of limited stage small cell lung cancer begins with a firm pathologic diagnosis and careful staging. Patients with adequate pulmonary function, ambulatory performance status, and no evidence of metastatic disease outside a “tolerable” local radiotherapy volume should have consultation from both medical and radiation oncology disciplines for planning of integrated therapy. The chemotherapy prescription recommended is cisplatin plus etoposide at standard doses for four chemotherapy cycles. Thoracic irradiation should be administered concurrently with the first or second cycle of cisplatin and etoposide. Patients with complete response and excellent partial response should receive prophylactic cranial irradiation after completion of all chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Murray N: Small-cell lung cancer at the millennium: radiotherapy innovations improve survival while new chemotherapy treatments remain unproven. Clin Lung Cancer 2000, 1:181–190. Recent comprehensive review of management of SCLC.
Albain KS, Crowley JJ, LeBlanc M, et al.: Determinants of improved outcome in small cell lung cancer: an analysis of the 2580 patient Southwest Oncology Group data base. J Clin Oncol 1990, 8:1563–1574.
Siu LL, Shepherd FA, Murray N, et al.: Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 1996, 14:821–828.
Murray N, Coy P, Pater JL, et al.: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993, 11:336–344.
Pignon JP, Arriagada R, Ihde DC, et al.: A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992, 327:1618.
Perry MC, Herndon JE, Eaton WL, et al.: Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J Clin Oncol 1998, 16:2466–2467.
Work E, Nielsen O, Bentzen S, et al.: Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. J Clin Oncol 1997, 15:3030–3037.
Jeremic B, Shibamato Y, Acimovic L, et al.: Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited SCLC: a randomized study. J Clin Oncol 1997, 15:893–900.
Goto K, Nishiwaki Y, Takada M, et al.: Final results of a phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage SCLC: the Japan Clinical Oncology (JCOG) study [abstract]. Proc Am Soc Clin Oncol 1999, 18:468a.
Turrisi AT, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265–271. First controlled trial to demonstrate benefit of intensive early thoracic irradiation.
Bonner JA, Sloan JA, Shanahan TG, et al.: Phase III comparison of twice-daily split-course irradiation versus once-daily radiation for patients with limited stage small-cell lung cancer. J Clin Oncol 1999, 17:2681–2691.
Auperin A, Arriagada R, Pignon J, et al.: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999, 341:476–484. Demonstrates survival benefit of prophylactic cranial irradiation for LSCLC.
Gregor A, Cull A, Stephens RJ, et al.: Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicenter randomized trial. Eur J Cancer 1997, 33:1752–1758.
Bunn PA, Crowley J, Hazuka R, et al.: Chemoradio-therapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995, 13:1632–1641.
Tucker MA, Murray N, Shaw EG, et al.: Second primary cancers related to smoking and treatment of small-cell lung cancer. J Natl Cancer Inst 1997, 89:1782. Documents the high cumulative risk of second primary lung cancer in long-term survivors of LSCLC and the importance of smoking cessation.
Shepherd FA, Ginsberg RJ, Patterson GA, et al.: A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer. J Thorac Cardiovasc Surg 1989, 97:177–187.
Lad T, Piantadosi S, Thomas P, et al.: A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994, 106:320–325.
Feld R, Pater J, Goodwin PJ, et al.: The restaging of responding patients with limited small cell lung cancer: is it really useful? Chest 1993, 103:1010.
Goodwin PJ, Shepherd FA: Economic issues in lung cancer: a review. J Clin Oncol 1998, 16:3900–3912.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murray, N., Sheehan, F. Limited stage small cell lung cancer. Curr. Treat. Options in Oncol. 2, 63–70 (2001). https://doi.org/10.1007/s11864-001-0017-5
Issue Date:
DOI: https://doi.org/10.1007/s11864-001-0017-5